“: We reiterate our Overweight rating and $56 PT for SUPN stock. We believe the next 12-18 months will be an important period as the company’s pipeline development prowess is measured by pivotal data from the SPN-810 and SPN-812 clinical programs. We believe either program embodies commercial potential that could match or exceed combined revenues for Trokendi XR and Oxtellar XR. Consequently, although some investors may probe/clamor for evidence of growth through acquisition, we think successful development of either program will be the most important near-to-intermediate-term drivers of SUPN share value.”
According to TipRanks.com, Tanner is a 3-star analyst with an average return of 3.5% and a 49.2% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Aquinox Pharmaceuticals, and Amag Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Supernus Pharmaceuticals with a $56.50 average price target.
The company has a one-year high of $61.25 and a one-year low of $33.30. Currently, Supernus Pharmaceuticals has an average volume of 790.7K.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy.